M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: A pilot study

被引：6

作者：

Wang, Shu ^{[1
,2
]}

Xu, Guanghui ^{[1
,2
]}

Li, Mengbin ^{[1
,2
]}

Zheng, Jiyang ^{[1
,2
]}

Wang, Yuhao ^{[1
,2
]}

Feng, Xiangying ^{[1
,2
]}

Luo, Jialin ^{[1
,2
]}

Wang, Shibo ^{[1
]}

Liu, Huan ^{[1
]}

Duan, Weiming ^{[3
]}

Zhang, Hushan ^{[3
]}

Huang, Depei ^{[3
]}

Zhao, Feilong ^{[3
]}

Nie, Yongzhan ^{[1
]}

Yang, Jianjun ^{[1
,2
]}

机构：

[1] Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Peoples R China

[2] Fourth Mil Med Univ, Xijing Hosp Digest Surg, Xian, Peoples R China

[3] 3D Med Inc, Med Dept, Shanghai, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2023年 / 13卷

关键词：

esophageal squamous cell carcinoma; neoadjuvant therapy; camrelizumab; M1; macrophage; immune microenvironment; SQUAMOUS-CELL CARCINOMA; ESOPHAGEAL CANCER; POLARIZATION; MULTICENTER; PROGRESSION; SURGERY; THERAPY; SAFETY;

D O I：

10.3389/fonc.2023.1139990

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IntroductionThe efficacy and safety of immunotherapy have been widely recognized in gastrointestinal-related cancers. However, the efficacy of neoadjuvant camrelizumab for locally advanced esophageal squamous cell carcinoma (ESCC) has not been firmly established. This study compared the efficacy of camrelizumab in combination with neoadjuvant DCF (docetaxel, cisplatin and fluorouracil), with DCF alone for ESCC, and exploring biomarkers related to immune infiltration of the ESCC immunotherapy response. MethodsWe enrolled and randomly assigned patients with stage II-IVa ESCC to two study treatments: camrelizumab combined with docetaxel, cisplatin and fluorouracil (DCF) regimen and DCF regimen alone. The tissue for multiplex immunofluorescence (mIF) was obtained before and after neoadjuvant therapy. The Response Evaluation Criteria in Solid Tumors RECIST Version 1.1 (RECIST 1.1) and Tumor Regression Grade (TRG) was used to evaluate efficacy. ResultsA total of 30 patients were enrolled in the study. Following neoadjuvant camrelizumab, the objective response rate (ORR) and the disease control rate (DCR) were 46.7% (7/15) and 95.7% (14/15), respectively. No patients reported complete remission, while ORR and DCR in the chemotherapy group were 26.7% (4/15) and 86.7% (13/15), respectively. R0 resection after neoadjuvant treatment was achieved in 3 out of 15 patients in the combined group and in all patients (15/15) in the chemotherapy group. In the combined group, M1-type tumor-associated macrophages and CD56dim NK cells were more abundant in responders than in non-responders (p < 0.05). A higher M1/M2 ratio was observed in responders (p < 0.05). With respect to the NGS, among the copy number amplified genes, the 11q13 amplicon (CCND1/FGF19/FGF4/FGF3) showed the highest frequency (47%, 7/15). ConclusionsNeoadjuvant camrelizumab combined with chemotherapy improved ORR in locally advanced ESCC. M1-type tumor-associated macrophages and CD56dim NK cells might be utilized to predict camrelizumab efficacy.

引用

页数：11

共 42 条

[1]

Bancewicz J, 2002, LANCET, V359, P1727

[2] Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers [J].

Chalabi, Myriam ;

Fanchi, Lorenzo F. ;

Dijkstra, Krijn K. ;

Van den Berg, Jose G. ;

Aalbers, Arend G. ;

Sikorska, Karolina ;

Lopez-Yurda, Marta ;

Grootscholten, Cecile ;

Beets, Geerard L. ;

Snaebjornsson, Petur ;

Maas, Monique ;

Mertz, Marjolijn ;

Veninga, Vivien ;

Bounova, Gergana ;

Broeks, Annegien ;

Beets-Tan, Regina G. ;

de Wijkerslooth, Thomas R. ;

van Lent, Anja U. ;

Marsman, Hendrik A. ;

Nuijten, Elvira ;

Kok, Niels F. ;

Kuiper, Maria ;

Verbeek, Wieke H. ;

Kok, Marleen ;

Van Leerdam, Monique E. ;

Schumacher, Ton N. ;

Voest, Emile E. ;

Haanen, John B. .

NATURE MEDICINE, 2020, 26 (04) :566-+

[3] Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations [J].

Chang, Jiang ;

Tan, Wenle ;

Ling, Zhiqiang ;

Xi, Ruibin ;

Shao, Mingming ;

Chen, Mengjie ;

Luo, Yingying ;

Zhao, Yanjie ;

Liu, Yun ;

Huang, Xiancong ;

Xia, Yuchao ;

Hu, Jinlin ;

Parker, Joel S. ;

Marron, David ;

Cui, Qionghua ;

Peng, Linna ;

Chu, Jiahui ;

Li, Hongmin ;

Du, Zhongli ;

Han, Yaling ;

Tan, Wen ;

Liu, Zhihua ;

Zhan, Qimin ;

Li, Yun ;

Mao, Weimin ;

Wu, Chen ;

Lin, Dongxin .

NATURE COMMUNICATIONS, 2017, 8

[4] Correlations of Tumor-associated Macrophage Subtypes with Liver Metastases of Colorectal Cancer [J].

Cui, Yun-Long ;

Li, Hui-Kai ;

Zhou, Hong-Yuan ;

Zhang, Ti ;

Li, Qiang .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (02) :1003-1007

[5] Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors [J].

Day, Daphne ;

Hansen, Aaron R. .

BIODRUGS, 2016, 30 (06) :571-584

[6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[7] PPAR-α Agonist Fenofibrate Suppressed the Formation of Ocular Surface Squamous Metaplasia Induced by Topical Benzalkonium Chloride [J].

He, Huan ;

Liang, Minghui ;

Li, Lan ;

Luo, Shunrong ;

Fang, Xie ;

He, Hui ;

Xiao, Xianwen ;

Wu, Huping ;

Lin, Zhirong .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (03)

[8] Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma [J].

He, Wenwu ;

Leng, Xuefeng ;

Mao, Tianqin ;

Luo, Xi ;

Zhou, Lingxiao ;

Yan, Jiaxin ;

Peng, Lin ;

Fang, Qiang ;

Liu, Guangyuan ;

Wei, Xing ;

Wang, Kangning ;

Wang, Chenghao ;

Zhang, Sha ;

Zhang, Xudong ;

Shen, Xudong ;

Huang, Depei ;

Yi, Huan ;

Bei, Ting ;

She, Xueke ;

Xiao, Wenguang ;

Han, Yongtao .

ONCOLOGIST, 2022, 27 (01) :E18-E28

[9] Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807) [J].

Hironaka, Shuichi ;

Tsubosa, Yasuhiro ;

Mizusawa, Junki ;

Kii, Takayuki ;

Kato, Ken ;

Tsushima, Takahiro ;

Chin, Keisho ;

Tomori, Akihisa ;

Okuno, Tatsuya ;

Taniki, Toshikatsu ;

Ura, Takashi ;

Matsushita, Hisayuki ;

Kojima, Takashi ;

Doki, Yuichiro ;

Kusaba, Hitoshi ;

Fujitani, Kazumasa ;

Taira, Koichi ;

Seki, Shiko ;

Nakamura, Tsutomu ;

Kitagawa, Yuko .

CANCER SCIENCE, 2014, 105 (09) :1189-1195

[10] Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study [J].

Huang, Jing ;

Xu, Jianming ;

Chen, Yun ;

Zhuang, Wu ;

Zhang, Yiping ;

Chen, Zhendong ;

Chen, Jia ;

Zhang, Helong ;

Niu, Zuoxing ;

Fan, Qingxia ;

Lin, Lizhu ;

Gu, Kangsheng ;

Liu, Ying ;

Ba, Yi ;

Miao, Zhanhui ;

Jiang, Xiaodong ;

Zeng, Ming ;

Chen, Jianhua ;

Fu, Zhichao ;

Gan, Lu ;

Wang, Jun ;

Zhan, Xianbao ;

Liu, Tianshu ;

Li, Zhiping ;

Shen, Lin ;

Shu, Yongqian ;

Zhang, Tao ;

Yang, Qing ;

Zou, Jianjun .

LANCET ONCOLOGY, 2020, 21 (06) :832-842

← 1 2 3 4 5 →